Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience.
Forty-six patients with progressive metastatic disease following initial response to tamoxifen therapy were treated with aminoglutethimide. Three patients (6%) achieved complete remission, 15 patients (33%) had partial response, and eight patients (17%) had stable disease. Twenty patients (44%) had progressive disease. The most common side effects were transient skin rash, lethargy, or dizziness. In four patients (7%), treatment was discontinued because of undesirable side effects within the first 2 weeks of the study. These data show that aminoglutethimide is an effective agent following tamoxifen therapy.
D000616:Aminoglutethimide / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D012871:Skin Diseases / Q000139:chemically induced; D012894:Sleep Stages / Q000187:drug effects; D013629:Tamoxifen / Q000627:therapeutic use*; D013997:Time Factors
D013629:Tamoxifen; D000616:Aminoglutethimide